Burns C. Blaxall, PhD, is the founding Executive Director of Precision Medicine at The Christ Hospital Health Network (TCHHN). He leads a transition from reactive to proactive healthcare delivery by harnessing the power of personal diagnostic and genomic data. Using approaches ranging from cutting edge hereditary disease risk assessment, genetic counseling and testing to pharmacogenomics and genome-guided clinical care pathways, Precision Medicine at TCHHN aims to provide proactive, individualized care for every patient.
Dr. Blaxall received his PhD in Pharmacology from the University of Colorado Health Sciences Center, followed by a postdoctoral fellowship at Duke University Medical Center. He held faculty positions at the University of Rochester Medical Center as well as at The University of Cincinnati and Cincinnati Children’s Hospital Medical Center, where he was Professor and founding Director of the Center for Translational Fibrosis Research, as well as Director of Translational Science and of the Heart Institute Clinical Research Core and Biorepository. He holds several patents, has published nearly 100 peer-reviewed manuscripts and has received numerous honors, including the Early Career Investigator Award and the Outstanding Achievement Award from the American Heart Association; most recently he was highlighted among the top six regional healthcare innovators by Cincinnati Magazine, and was named a Cincinnati Healthcare Hero. He has held extensive national and international leadership positions in numerous professional societies, chaired NIH peer-review panels and serves on the editorial board for numerous top professional journals. He is an elected fellow of several professional organizations (ACC, AHA, ISHR, APS) and currently serves in national leadership and advocacy positions for prominent professional societies in the fields of Precision Medicine and Pharmacogenomics.
